Radiation

QT Imaging’s Breast Acoustic CT™ Scanner Used in Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Women, Engineering, Manufacturing, Radiology, Consumer, Health, Science, Oncology, ACT, NAC, Partnership, Patient, Champaign–Urbana metropolitan area, Sunnybrook Health Sciences Centre, Biomarker, University of Illinois Urbana-Champaign, Cancer, University, Doctor of Philosophy, Electricity, MD, Computer engineering, Risk, Woman, Breast cancer, Safety, Radiation, Bangladesh Technical Education Board, Radiation therapy, Grainger College of Engineering, Medical imaging

This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).

Key Points: 
  • This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).
  • As part of this grant, Breast Acoustic CT™ (ACT) quantitative images with independent biomarkers known to be sensitive to cancer will be collected, and the response of cancer to therapy, will be derived from quantitative ultrasound based on backscatter analysis.
  • This collaboration also addresses the ongoing clinical need in breast cancer therapy for the development of an inexpensive, robust, and accurate technique to identify the response, within weeks, of breast cancer to neoadjuvant chemotherapy.
  • The early identification of non-responders to NAC or any cancer treatment remains a highly significant medical problem and necessary for adaptive precision medicine.

Stratasys to Test 3D-Printed Material Performance on Moon

Retrieved on: 
Tuesday, March 12, 2024
Research, Hardware, Robotics, Electronic Design Automation, Technology, Other Manufacturing, Satellite, Science, Engineering, Other Technology, Aerospace, Other Science, Manufacturing, Temperature, Radiation, ESD, FDM, Northrop Grumman, Travel, Electronics, Moon, 3D, Orion, Housing, Grumman, Part, Tungsten, Multimedia, Gamma, X-ray, Stratasys, 3D printing

Stratasys Ltd. (NASDAQ: SSYS), a leader in polymer 3D printing solutions, today announced that it will provide 3D-printed materials for an upcoming lunar mission to test their performance on the surface of the moon.

Key Points: 
  • Stratasys Ltd. (NASDAQ: SSYS), a leader in polymer 3D printing solutions, today announced that it will provide 3D-printed materials for an upcoming lunar mission to test their performance on the surface of the moon.
  • The SSTEF-1 project focuses on technology development for space infrastructure and capabilities for the moon and near-earth space.
  • (Photo: Business Wire)
    In this moon mission, Stratasys will provide 3D-printed samples that will be brought to the lunar surface by an unmanned lander in a carrier structure 3D-printed by Stratasys.
  • The first experiment assesses the performance of a sample coupon part made with Stratasys’ Antero® 800NA FDM® filament filled with tungsten.

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

Retrieved on: 
Monday, March 11, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Research, Software, General Health, Genetics, Health Technology, Science, Data Management, Clinical Trials, Biopsy, OS, HER2, Cancer, Radiation, Kingdom of Poland, Anthracycline, Survival, Disease, Neoadjuvant therapy, CBM, International Cancer Genome Consortium, TNM, University, Patient, Rated R, NGS, Biomarker, MSI, Artificial intelligence, Standard of care, DFS, TRI, MD, Medicine, TRG, Platinum, Publication, Biosimulation, OGA, Whole genome sequencing, PD-L1, Taxane, Medical imaging

The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).

Key Points: 
  • The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).
  • Despite progress in gastroesophageal cancer therapy, only a small proportion of patients attain long-term survival.
  • This study concluded that TRI scores for gastroesophageal adenocarcinoma patients predict OS and DFS beyond clinical factors.
  • These results highlight the clinical value of employing Cellworks biosimulation for personalized therapy selection and warrant additional clinical evaluation.

Amentum Awarded $245 Million IAC MAC Contract to Deliver Microelectronics Capabilities for the U.S. Navy

Retrieved on: 
Monday, March 11, 2024
Research, Other Defense, Contracts, Technology, Defense, Semiconductor, Science, Government Technology, Engineering, Other Technology, Manufacturing, Military, Surge (drink), GXM, Radiation, DTIC, Weapon, RDT, Naval Surface Warfare Center, IDEA, Laboratory, NSWC, Defense Technical Information Center, Ecosystem, SSP, Navy, 3D printing

The contract will strengthen our nation’s deterrence and defense by delivering state-of-the-art services and independent data driven solutions and establishing GXM as the national leader in high-reliability, radiation hardened microelectronics.

Key Points: 
  • The contract will strengthen our nation’s deterrence and defense by delivering state-of-the-art services and independent data driven solutions and establishing GXM as the national leader in high-reliability, radiation hardened microelectronics.
  • “Amentum will leverage our digital engineering ecosystem and model-based system engineering expertise to enhance capabilities for strategic radiation hardened microelectronics," said Jill Bruning, President of Amentum’s Engineering, Science, and Technology Group.
  • This will include updating and enhancing related microelectronics T&E facilities and laboratories; related capabilities associated with the Navy’s Fleet Ballistic Missile system and Strategic Weapons System; and DoD strategic weapons platforms employing advanced and critical microelectronics technologies.
  • Amentum will also support the Navy by increasing prototyping and test surge capacity and providing radiation hardened and survivability subject matter expertise.

RSNA: Early Coronary Disease, Impaired Heart Function Found in Asymptomatic People with HIV

Retrieved on: 
Thursday, April 4, 2024
Biomedicine, Cardiovascular disease, MRI, Coronary artery disease, HIV, Didanosine, Viral load, Education, Patient, Facial muscles, Research, Kidney, University, Death, Physical examination, NIH, Society, Life expectancy, Risk, Moyamoya disease, OAK, World Health Organization, RSNA, DRS, Heart, Radiation, Bangladesh Technical Education Board, Digestive, Synthetic control method, Health, Person, Pharmaceutical industry

OAK BROOK, Ill., April 4, 2024 /PRNewswire-PRWeb/ -- A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV. The study was published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV.
  • The ability to detect early coronary artery disease in persons living with HIV and potentially prevent detrimental effects on the heart muscle is important.
  • This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function.
  • "This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function."

Medicare Coverage Is Threatened for the 134,000 North Carolinians Likely to Get Skin Cancer this Year

Retrieved on: 
Tuesday, April 2, 2024
Dermatology, DART, Skin cancer, Federation, Diabetes, Patient, Research, Mohs surgery, Policy, Cancer, Insurance, Judgement, Blue Cross, Blue Shield, Carcinoma, Radiation, Medicare, FDA, Pain, Hearing, Medical imaging

Palmetto GBA, a subsidiary of Blue Cross and Blue Shield of South Carolina, is authorized by the federal government to regulate Medicare in North Carolina and six other states.

Key Points: 
  • Palmetto GBA, a subsidiary of Blue Cross and Blue Shield of South Carolina, is authorized by the federal government to regulate Medicare in North Carolina and six other states.
  • Palmetto is moving quickly to cancel coverage, which has been in effect nearly 10 years.
  • Medicare and private insurers should provide coverage for Image-Guided SRT whenever it's deemed the most suitable therapy by patients and their healthcare providers.
  • Consumers who care about keeping their insurance coverage for the nonsurgical treatment should write to the panel by May 11, at [email protected] .

Medicare Coverage Is Threatened for the 96,000 Tennesseans Likely to Get Skin Cancer this Year

Retrieved on: 
Tuesday, April 2, 2024
Dermatology, DART, Skin cancer, Federation, Diabetes, Patient, Research, Mohs surgery, Policy, Cancer, Insurance, Judgement, Blue Cross, Carcinoma, Blue Shield, Radiation, Medicare, FDA, Pain, Hearing, Medical imaging

Palmetto is moving quickly to cancel coverage, which has been in effect nearly 10 years.

Key Points: 
  • Palmetto is moving quickly to cancel coverage, which has been in effect nearly 10 years.
  • That would leave coverage only for procedures at radiation therapy cancer centers or for Mohs surgery in most cases, although Mohs surgeons are relatively few in number and are rarely found in rural communities.
  • Medicare and private insurers need to ensure coverage for Image-Guided SRT whenever it's considered the most appropriate treatment by patients and their medical teams.
  • Consumers who care about keeping their insurance coverage for the nonsurgical treatment should write to the panel by May 11, at [email protected] .

Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen

Retrieved on: 
Tuesday, April 2, 2024
Radiation, Convergent, Prostate cancer, Patient, IND, Alpha, Therapy, Cancer, Safety, CSO, PSA, FDA, Food, Pharmaceutical industry

CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for the treatment of prostate cancer and other cancers, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the investigational new drug ("IND") application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer.

Key Points: 
  • "Receiving clearance of our IND is a significant milestone for Convergent Therapeutics," said Convergent's Co-founder and CEO, Philip Kantoff, MD.
  • "Importantly, patients also showed minimal side effects in Phase 1/2 trials.
  • CONV01-α's ideal biodistribution delivers potent alpha particles while avoiding immediate and significant salivary gland toxicity as well as the potential delayed renal toxicity," said Neil Bander, MD, Convergent's Co-founder and CSO.
  • "CONV01-α's design increases delivery of tumor-killing radiation to malignant cells while greatly reducing both off-tumor effects and the amount of radiation delivered per dose, thereby improving both treatment efficacy and safety."

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Retrieved on: 
Tuesday, April 2, 2024
Toxicity, Radiation, Sintilimab, NMPA, Endometrial cancer, Disease, DCR, New Drug Application, Patient, Neoplasm, NDA, Cancer, Breakthrough therapy, Senior, HCM, HKEX, Dor, IRC, Prognosis, PFS, Ophthalmology, Pharmaceutical industry

The NDA is supported by data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase 2 study investigating sintilimab in combination with fruquintinib in endometrial cancer patients who experienced disease recurrence, disease progression or intolerable toxicity  with treatment on platinum-based doublet chemotherapy.

Key Points: 
  • The NDA is supported by data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase 2 study investigating sintilimab in combination with fruquintinib in endometrial cancer patients who experienced disease recurrence, disease progression or intolerable toxicity  with treatment on platinum-based doublet chemotherapy.
  • We are excited about the NDA acceptance and priority review designation, which increases our potential to bring a new treatment option to endometrial cancer patients, and concurrently strengthens the leadership position of TYVYT® in China."
  • We look forward to bringing this much-awaited treatment advancement to endometrial cancer patients to improve their treatment outcome."
  • The NMPA granted Breakthrough Therapy designation to the combination of sintilimab and fruquintinib for this potential indication in July 2023.

ACTREC Researchers Show Cancer Treatments May be Promoting its Spread

Retrieved on: 
Thursday, March 28, 2024
Research, Education, ACTREC, Glomus tumor, Neoplasm, DNA, Mouse, PLOS One, Radiation, Protein, Treatment, PLOS, Blood, Lymphatic system, Metastasis

MUMBAI, India, March 28, 2024 /PRNewswire/ -- Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing metastasis remains a major goal in oncology.

Key Points: 
  • In a step towards these efforts, Prof. Indraneel Mittra from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India, has shed light on what causes metastasis.
  • Their findings, published in PLOS One result from experiments in mice grafted with human breast cancer cells (xenografts) to induce cancer.
  • Prof. Mittra concludes,"Future long-term experiments should explore whether cfChP-deactivating agents given concurrently with anti-cancer treatments could help prevent metastatic spread.
  • When used as adjuncts to cancer treatment, these agents would have the added advantage of preventing some of the toxic side effects of chemotherapy and radiotherapy."